IDEXX Laboratories, Inc. (IDXX) Shares Sold by Mitsubishi UFJ Trust & Banking Corp

Mitsubishi UFJ Trust & Banking Corp reduced its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.7% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 185,512 shares of the company’s stock after selling 1,321 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp owned approximately 0.21% of IDEXX Laboratories worth $28,845,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. D.A. Davidson & CO. boosted its holdings in shares of IDEXX Laboratories by 160.4% during the 2nd quarter. D.A. Davidson & CO. now owns 625 shares of the company’s stock valued at $100,000 after buying an additional 385 shares in the last quarter. Sun Life Financial INC boosted its holdings in shares of IDEXX Laboratories by 9,085.7% during the 2nd quarter. Sun Life Financial INC now owns 643 shares of the company’s stock valued at $104,000 after buying an additional 636 shares in the last quarter. BB&T Investment Services Inc. bought a new position in IDEXX Laboratories in the 2nd quarter worth about $104,000. Coastline Trust Co bought a new position in IDEXX Laboratories in the 2nd quarter worth about $202,000. Finally, Flagship Harbor Advisors LLC boosted its stake in IDEXX Laboratories by 16.7% in the 2nd quarter. Flagship Harbor Advisors LLC now owns 1,512 shares of the company’s stock worth $243,000 after purchasing an additional 216 shares in the last quarter. 86.80% of the stock is currently owned by institutional investors and hedge funds.

A number of equities analysts recently issued reports on IDXX shares. Zacks Investment Research upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 price target on the stock in a research note on Tuesday, October 24th. Stifel Nicolaus reiterated a “buy” rating and issued a $185.00 price target on shares of IDEXX Laboratories in a research note on Tuesday, October 24th. Canaccord Genuity reiterated a “buy” rating and issued a $180.00 price target on shares of IDEXX Laboratories in a research note on Friday, October 6th. Finally, Bank of America upgraded shares of IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 price target on the stock in a research note on Wednesday, August 23rd. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. IDEXX Laboratories currently has a consensus rating of “Hold” and an average price target of $173.67.

In other news, Chairman Jonathan W. Ayers sold 54,000 shares of the company’s stock in a transaction dated Tuesday, November 7th. The shares were sold at an average price of $151.32, for a total transaction of $8,171,280.00. Following the completion of the sale, the chairman now owns 1,064,573 shares of the company’s stock, valued at approximately $161,091,186.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jonathan W. Ayers sold 18,000 shares of the company’s stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $153.75, for a total transaction of $2,767,500.00. Following the sale, the chief executive officer now directly owns 1,064,573 shares of the company’s stock, valued at approximately $163,678,098.75. The disclosure for this sale can be found here. Insiders have sold a total of 110,000 shares of company stock valued at $16,686,200 in the last ninety days. Insiders own 2.77% of the company’s stock.

IDEXX Laboratories, Inc. (NASDAQ IDXX) opened at $159.78 on Wednesday. IDEXX Laboratories, Inc. has a 52-week low of $113.71 and a 52-week high of $173.01. The company has a debt-to-equity ratio of -12.48, a current ratio of 0.95 and a quick ratio of 0.77. The firm has a market capitalization of $13,518.90, a PE ratio of 52.19, a price-to-earnings-growth ratio of 2.34 and a beta of 0.42.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Tuesday, October 31st. The company reported $0.79 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.05. IDEXX Laboratories had a negative return on equity of 336.64% and a net margin of 14.55%. The business had revenue of $492.00 million during the quarter, compared to analyst estimates of $492.94 million. During the same quarter in the previous year, the firm earned $0.62 EPS. IDEXX Laboratories’s revenue was up 9.7% on a year-over-year basis. equities analysts forecast that IDEXX Laboratories, Inc. will post 3.24 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This article was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://stocknewstimes.com/2017/12/06/idexx-laboratories-inc-idxx-shares-sold-by-mitsubishi-ufj-trust-banking-corp.html.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply